Not yet, says Weeden’s Michael Purves–but it’s sure time to hedge. He explains why:
Special to The ChronicleHedging biotechnology stocks once again appears timely. This sector, a stand out in 2012 and 2013 is still outperforming the broader market (iShares Nasdaq Biotechnology ETF (IBB) up 12.4% ytd vs S&P 500 up 7.5%). None the less, we think this sector is increasingly vulnerable to sector rotation. Should a broader sell off occur, this sector will likely be among the most aggressively sold given the very significant gains. The technicals are weakening and the recent rallies appear to be more squeeze driven. This sector may have enduring fundamental legs, but investors should remember that the March sell off brought the sector down 25% in six weeks.
Biotech stocks aren’t falling much today, however. The iShares Nasdaq Biotechnology ETF has dropped 0.5% to $254.31, while Biogen Idec (BIIB) is off 0.3% to $335.85 and Amgen (AMGN) and Regeneron Pharmaceuticals (REGN) are little changes at $122.25 and $304.41, respectively.
5 Best Regional Bank Stocks To Own Right Now: AFC Enterprises Inc.(AFCE)
AFC Enterprises, Inc. develops, operates, and franchises quick-service restaurants under the trade names of Popeyes Chicken & Biscuits and Popeyes Louisiana Kitchen. As of December 25, 2011, it operated and franchised 2,035 Popeyes restaurants in 45 states, the District of Columbia, Puerto Rico, Guam, the Cayman Islands, and 25 foreign countries. The company was founded in 1972 and is headquartered in Atlanta, Georgia.
Advisors' Opinion:- [By AnnaLisa Kraft]
AFC Enterprises (NASDAQ: AFCE ) , which owns the Popeye's Louisiana Kitchen quick- serve chain, once an undiscovered gem, has now soared 66% over the last year.
- [By John Reese]
Indeed, in 2013, the Greenblatt-based portfolio has bounced back strong, returning more than 50%. Below is a look at its current holdings.
EBIX, Inc. (EBIX)
Western Refining (WNR)
DirecTV (DTV)
ITT Educational Services (ESI)
Science Applications International (SAIC)
Weight Watchers International (WTW)
ConocoPhillips (COP)
AmSurg Corp. (AMSG)
PDL BioPharma (PDLI)
AFC Enterprises (AFCE)
Subscribe to Validea here��/p>
- [By Seth Jayson]
AFC Enterprises (Nasdaq: AFCE ) reported earnings on May 29. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended April 21 (Q1), AFC Enterprises beat expectations on revenues and met expectations on earnings per share.
Top 10 Gas Utility Stocks To Watch Right Now: Market Leader Inc(LEDR)
Market Leader, Inc., together with its subsidiaries, provides software-as-a-service-based business and marketing solutions for real estate professionals primarily in the United States and Canada. It offers real estate agents and brokerage companies with software-as-a-service based products, as well as online lead-generation, online prospect management, online real estate portal content and advertising, and customer coaching and training solutions. The company also offers consumers with free access to the information and tools they need throughout the home buying and selling process through its national consumer real estate sites. Its consumer Web sites include: JustListed.com, a service that notifies home buyers as soon as new homes hit the market; HouseValues.com, a service, which provides home sellers with market valuations of their current homes; and HomePages.com, a real estate portal that enables consumers to see the home listings in their area, view detailed neighbor hood and school data, compare recent home sales, find local real estate agents, and find the value of their own homes. In addition, the company offers Growth Leader, a Website and customer relationship management tool for real estate agents; RealtyGenerator, a lead-generation and lead management system for real estate brokerage offices; and ActiveRain.com that provides professional networking, referral, recruitment, content syndication, and online marketing services for professionals in real estate and related businesses. Market Leader, Inc. markets its products to individual agents and brokerage offices directly, as well as through marketing partnerships with real estate franchise networks. The company was formerly known as Housevalues, Inc. and changed its name to Market Leader, Inc. in November 2008. Market Leader, Inc. was founded in 1999 and is headquartered in Kirkland, Washington.
Advisors' Opinion:- [By Michael Lewis]
For a bit of context, competitor Trulia (NYSE: TRLA ) is in negotiations to buy Market Leader (NASDAQ: LEDR ) for $355�million. Market Leader is a smaller (and growing) business that's similar to both Zillow and Trulia. Since Market Leader is still earnings negative, we can't compare it on a P/FCF basis, but we can look at other metrics. For one, Market Leader trades at a still-ridiculous-but-slightly less-so 57.2 times forward earnings. It trades at 6.4 times last year's sales. Zillow trades at 16.4 times last year's sales. Management expects sales to hit (on the high end) $182 million -- that implies a price of 10.55 times forward sales. If they double a year or two after, which would be unbelievably phenomenal, it would trade at 5.3 times sales.
Top 10 Gas Utility Stocks To Watch Right Now: Receptos Inc (RCPT)
Receptos, Inc. (Receptos), incorporated on June 9, 2008, is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for immune disorders. The Company�� product candidates span three specialty disease areas. The Company�� lead asset, RPC1063, is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Its second asset, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. RPC1063 is an oral, once daily, selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) modulator. RPC4046 is a monoclonal antibody selective to interleukin-13 (IL-13) and produced by recombinant deoxyribonucleic acid (DNA) technology.
As of December 31, 2012, RPC1063 was being tested in the Phase II portion of an accelerated design, randomized Phase II/III study for the treatment of RMS. In addition, Receptos has obtained special protocol assessment (SPA) agreement from the United States food and drug administration (FDA) on its clinical trial design for the planned Phase III portion of the Phase II/III study, as well as a second planned RMS Phase III study. RPC1063 is also being tested in a randomized Phase II study for the treatment of ulcerative colitis (UC), a gastrointestinal (GI) disea se.
As of December 31, 2012, the Company was enrolling a randomized Phase II study evaluating the ability of RPC1063 to induce clinical remission in patients with moderately-to-severely active UC called TOUCHSTONE. The Company�� second asset, RPC4046 for the treatment of EoE, builds upon its competencies in immunology and GI diseases. In-licensed from AbbVie Bahamas Ltd. and AbbVie Inc. (AbbVie) RPC4046 is a monoclonal antibody directed against the IL-13 target, which has been validated in Asthma, a predominantly allergic/immune-mediated disorder.
Advisors' Opinion:- [By RichardCox]
For those willing to take on some added volatility (and potential for increased risk based on less diversification), investors can look at Receptos Inc. (RCPT), to play this year's momentum in IPO entries. Enhanced expectations for the company's IPO drove the company to raise its initial share offering to 5.2 million shares. Receptos has reached late-stage development for its oral treatment for multiple sclerosis (MS). MS treatments are dominated by industry heavyweights but MS pills are expected to surge in the next few years because oral treatments are becoming more efficient than injected therapies, and can cater to a broader consumer base. Being a new company, the Receptos chart only offers limited incite, and will not be included here.
- [By Ben Levisohn]
Yes, say the folks at Nomura, who recommend buying�Celgene (CELG), Receptos
(RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why: - [By Roberto Pedone]
Receptos (RCPT) is a biopharmaceutical company engaged in discovering, developing and commercializing therapeutics for immune disorders. This stock closed up 5% at $23.19 in Monday's trading session.
Monday's Volume: 69,000
Three-Month Average Volume: 55,356
Volume % Change: 50%From a technical perspective, RCPT ripped higher here right above some key near-term support at $21 with decent upside volume. This move is quickly pushing shares of RCPT within range of triggering a major breakout trade. That trade will hit if RCPT manages to take out its all-time high at $25 with high volume.
Traders should now look for long-biased trades in RCPT as long as it's trending above support at $21 and then once it sustains a move or close above its all-time high at $25 with volume that's near or above 55,356 shares. If that breakout hits soon, then RCPT will set up to enter new all-time-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $30 to $35.
- [By John Udovich]
Small cap �biopharmaceutical stock Receptos Inc (NASDAQ: RCPT) was one of the many hot biotech IPOs of last year and its also up 72.4% since the start of this year alone, meaning its time to take a closer look at this small cap stock with potential treatments for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD) along with the performance of biotech ETF benchmarks like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
Top 10 Gas Utility Stocks To Watch Right Now: SVB Financial Group(SIVB)
SVB Financial Group, a diversified financial services company, provides various banking and financial products and services. The company offers deposit products, such as traditional deposit and checking accounts, certificates of deposit, money market accounts, and sweep accounts, as well as lockbox and merchant services; and lending products and services, including traditional term loans, equipment loans, asset-based loans, revolving lines of credit, accounts-receivable-based lines of credits, capital call lines of credits, and credit cards. It also provides cash management products and services comprising wire transfer and automated clearing house payment services, collection services, disbursement services, electronic funds transfers, and online banking services. In addition, the company offers foreign exchange services; letters of credit, including export, import, and standby letters of credit; investment services and solutions; brokerage; asset management; investment a dvisory services, such as outsourced treasury services; and non-banking products and services, such as funds management, venture capital/private equity investment, and equity valuation services. Further, it provides private banking services comprising mortgages, home equity lines of credit, restricted stock purchase loans, and other secured and unsecured lending services. As of March 09, 2012, the company operated 26 offices in the United States and 7 offices internationally. It serves customers in the technology, venture capital/private equity, life science, wine, and clean tech industries. The company was founded in 1982 and is headquartered in Santa Clara, California.
Advisors' Opinion:- [By Will Ashworth]
While airlines have their ups and downs, Copa is about the best I can think of to weather the storm.
Best Stocks #4 (Midcap): SVB Financial (SIVB)
I never would have thought one of my picks for the next 20 years would be a bank — let alone one that focuses on entrepreneurs — but here I am.
- [By John Maxfield]
Given that you clicked on this article, it seems safe to assume you either own stock in SVB Financial (NASDAQ: SIVB ) or are considering buying shares in the near future. If so, then you've come to the right place. The table below reveals the nine most critical numbers that investors need to know about SVB Financial stock before deciding whether to buy, sell, or hold it.
Top 10 Gas Utility Stocks To Watch Right Now: Athersys Inc.(ATHX)
Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its clinical development programs are focused on treating cardiovascular disease, neurological conditions, inflammatory and immune disorders, and other conditions. Its product pipeline includes MultiStem, a novel allogeneic approach to stem cell therapy and regenerative medicine for treating a range of diseases. The company is also involved in the development of novel small molecule compounds for applications in indications, such as obesity and other areas, including the treatment of neurological conditions, and for the modulation of stem cells or related applications in the regenerative medicine area. It has product co-development collaboration with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease for the worldwide market; Angiotech Pharmaceuticals, Inc. to develop and commerciali ze MultiStem to treat certain cardiovascular diseases, such as acute myocardial infarction; and RTI Biologics, Inc. to develop and commercialize biologic implants for certain orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
Advisors' Opinion:- [By Roberto Pedone]
Athersys (ATHX) is a biopharmaceutical company focused in the field of regenerative medicine. This stock closed up 4% to $1.79 in Thursday's trading session.
Thursday's Range: $1.68-$1.80
52-Week Range: $0.95-$2.42
Thursday's Volume: 270,000
Three-Month Average Volume: 323,188From a technical perspective, ATHX bounced notably higher here right off its 50-day moving average of $1.67 with decent upside volume. This stock recently pulled back from $1.99 to its 50-day at $1.67. Shares of ATHX may now be down with that pullback, since the stock is starting to trend higher and move within range of triggering a near-term breakout trade. That trade will hit if ATHX manages to take out some near-term overhead resistance levels at $1.90 to $1.99 with high volume.
Traders should now look for long-biased trades in ATHX as long as it's trending above its 50-day at $1.67 and then once it sustains a move or close above those breakout levels with volume that hits near or above 323,188 shares. If that breakout triggers soon, then ATHX will set up to re-test or possibly take out its next major overhead resistance levels at $2.16 to $2.25. Any high-volume move above those levels will put its 52-week high at $2.42 into range for shares of ATHX.
- [By Lisa Levin]
Athersys (NASDAQ: ATHX) shares fell 56.04% to reach a new 52-week low of $1.20 on failed trial results for ulcerative colitis.
Posted-In: 52-Week LowsNews Movers & Shakers Intraday Update Markets
Top 10 Gas Utility Stocks To Watch Right Now: Tractebel Energia SA (TBLE3)
Tractebel Energia SA (Tractebel Energia) is a Brazil-based company involved in the energy sector. The Company is engaged in the generation and sale of electric power generated by its assets or acquired through near and long-term agreements. In addition, it provides online customer services to its customers. Tractebel Energia operates power plants in the Brazilian states of Santa Catarina, Rio Grande do Sul, Parana, Sao Paulo, Mato Grosso do Sul, Mato Grosso, Goias, Ceara, Piaui, Minas Gerais, Tocantins and Maranhao. The Company generates energy through hydroelectric power plants, thermoelectric plants, small hydroelectric power plants, wind farms and biomass fired power plants. The Company is controlled by GDF SUEZ Energy Latin America Participacoes Ltda. Advisors' Opinion:- [By Patricia Lara]
The state-run water company�� market value rose to a record $11.1 billion at the end of last month, narrowing the gap to generator Tractebel Energia SA (TBLE3) to about $360.7 million, data compiled by Bloomberg show. That�� down from $1 billion at the end of last year and $3.89 billion at the start of 2012.
Top 10 Gas Utility Stocks To Watch Right Now: Carmike Cinemas Inc.(CKEC)
Carmike Cinemas, Inc. operates as a digital cinema and 3D motion picture exhibitor in the United States. It operates theatres that show films on a first-run basis; and discount theatres. The company serves small to mid-size non-urban markets. As of December 31, 2011, it owned, operated, or had an interest in 237 theatres with 2,254 screens located in 35 states. The company was founded in 1982 and is headquartered in Columbus, Georgia.
Advisors' Opinion:- [By Chad Fraser] Christmas is a time for good cheer, reflection and spending time with friends and family. Here are four stocks that reflect the season, ranging from Christmas tree providers to toymakers and beyond:
Weyerhaeuser (NYSE: WY): Some little-known Christmas tree facts: there are 25 million to 30 million sold in the U.S. every year, with about 350 million currently growing in the country. It takes an average of seven years to grow a Christmas tree to its proper height.
Most Christmas tree farms are privately owned, but they need to get good seedlings from somewhere, so many turn to timber company Weyerhaeuser, which grows the most popular species—including balsam fir, Douglas fir, Scotch pine and white pine.
Weyerhaeuser controls about 6 million acres of timberland, with about a third of that in the Pacific Northwest, which is America’s most prolific lumber-producing region thanks to its cool, damp climate and considerable rainfall.
“The fact that it’s the largest timber producer in the Pacific Northwest makes Weyerhaeuser extremely attractive, because the company’s location gives it easy export access to China,” wrote Investing Daily analyst Benjamin Shepherd in a December 13 article. “This location also leaves it well-placed to pick up the supply slack created by lower production caps in Canada, which is typically a key Chinese supplier.”
Mattel (NYSE: MAT) is proving that the most traditional toys you can think of—dolls—still have a place under the tree, even in the digital age. As we reported on October 16, Mattel’s doll lineup was the main reason why its third-quarter earnings surged past Wall Street estimates.
The company’s strength is centered on its ability to come up with popular new dolls while reimagining the tried-and-true. Right now, its Monster High franchise, which it rolled out in 2010, is stealing the show: the brand’s p
No comments:
Post a Comment